Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective

Mitchell Kamrava; David Gius; Giovanna Casagrande; Elise Kohn

doi:10.1016/j.arr.2009.10.007

Will targeting insulin growth factor help us or hurt us? An oncologist's perspective

Mitchell Kamrava, David Gius, Giovanna Casagrande, Elise Kohn^*

^*Corresponding author for this work

Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The insulin/insulin growth factor (IGF) pathway is a critical mediator of longevity and aging. Efforts to extend longevity by altering the insulin/IGF pathway may have varying effects on other physiological processes. Reduced insulin/IGF levels may decrease the incidence of certain cancers as well as the risk of developing metastatic disease. However, it may also increase the risk of developing cardiovascular disease as well as cardiovascular related mortality. Pursuing the right insulin/IGF pathway targets will require striking a balance between inhibiting cancer cell development and progression and avoiding damage to tissues under normal insulin/IGF-mediated control. This review will discuss the roles of the insulin/IGF pathway in aging and longevity and the development of cancer cell metastasis and considerations in taking insulin/IGF directed targets to the oncology clinic.

Original language	English (US)
Pages (from-to)	62-70
Number of pages	9
Journal	Ageing Research Reviews
Volume	10
Issue number	1
DOIs	https://doi.org/10.1016/j.arr.2009.10.007
State	Published - Jan 2011

Keywords

Aging
Cancer
Insulin growth factor

ASJC Scopus subject areas

Biotechnology
Biochemistry
Aging
Molecular Biology
Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.arr.2009.10.007

Cite this

@article{02363526180a45ed8035281b8957414c,

title = "Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective",

abstract = "The insulin/insulin growth factor (IGF) pathway is a critical mediator of longevity and aging. Efforts to extend longevity by altering the insulin/IGF pathway may have varying effects on other physiological processes. Reduced insulin/IGF levels may decrease the incidence of certain cancers as well as the risk of developing metastatic disease. However, it may also increase the risk of developing cardiovascular disease as well as cardiovascular related mortality. Pursuing the right insulin/IGF pathway targets will require striking a balance between inhibiting cancer cell development and progression and avoiding damage to tissues under normal insulin/IGF-mediated control. This review will discuss the roles of the insulin/IGF pathway in aging and longevity and the development of cancer cell metastasis and considerations in taking insulin/IGF directed targets to the oncology clinic.",

keywords = "Aging, Cancer, Insulin growth factor",

author = "Mitchell Kamrava and David Gius and Giovanna Casagrande and Elise Kohn",

note = "Funding Information: This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research .",

year = "2011",

month = jan,

doi = "10.1016/j.arr.2009.10.007",

language = "English (US)",

volume = "10",

pages = "62--70",

journal = "Ageing Research Reviews",

issn = "1568-1637",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Will targeting insulin growth factor help us or hurt us?

T2 - An oncologist's perspective

AU - Kamrava, Mitchell

AU - Gius, David

AU - Casagrande, Giovanna

AU - Kohn, Elise

N1 - Funding Information: This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research .

PY - 2011/1

Y1 - 2011/1

N2 - The insulin/insulin growth factor (IGF) pathway is a critical mediator of longevity and aging. Efforts to extend longevity by altering the insulin/IGF pathway may have varying effects on other physiological processes. Reduced insulin/IGF levels may decrease the incidence of certain cancers as well as the risk of developing metastatic disease. However, it may also increase the risk of developing cardiovascular disease as well as cardiovascular related mortality. Pursuing the right insulin/IGF pathway targets will require striking a balance between inhibiting cancer cell development and progression and avoiding damage to tissues under normal insulin/IGF-mediated control. This review will discuss the roles of the insulin/IGF pathway in aging and longevity and the development of cancer cell metastasis and considerations in taking insulin/IGF directed targets to the oncology clinic.

AB - The insulin/insulin growth factor (IGF) pathway is a critical mediator of longevity and aging. Efforts to extend longevity by altering the insulin/IGF pathway may have varying effects on other physiological processes. Reduced insulin/IGF levels may decrease the incidence of certain cancers as well as the risk of developing metastatic disease. However, it may also increase the risk of developing cardiovascular disease as well as cardiovascular related mortality. Pursuing the right insulin/IGF pathway targets will require striking a balance between inhibiting cancer cell development and progression and avoiding damage to tissues under normal insulin/IGF-mediated control. This review will discuss the roles of the insulin/IGF pathway in aging and longevity and the development of cancer cell metastasis and considerations in taking insulin/IGF directed targets to the oncology clinic.

KW - Aging

KW - Cancer

KW - Insulin growth factor

UR - http://www.scopus.com/inward/record.url?scp=78650232632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650232632&partnerID=8YFLogxK

U2 - 10.1016/j.arr.2009.10.007

DO - 10.1016/j.arr.2009.10.007

M3 - Review article

C2 - 19896561

AN - SCOPUS:78650232632

VL - 10

SP - 62

EP - 70

JO - Ageing Research Reviews

JF - Ageing Research Reviews

SN - 1568-1637

IS - 1

ER -